Advice
following a full submission
calcium acetate 435mg/magnesium carbonate 235mg tablet (Osvaren®) is not recommended for use within NHS Scotland.
Indication under review: treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis).
The combined preparation of calcium acetate/magnesium carbonate has been shown to reduce hyperphosphataemia associated with chronic renal disease.
However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice124KB (PDF)
Medicine details
- Medicine name:
- calcium acetate and magnesium carbonate (Osvaren)
- SMC ID:
- 693/11
- Indication:
- Hyperphosphataemia (elevated serum phosphate levels) associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis)
- Pharmaceutical company
- Fresenius Medical Care (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 April 2011